Novo Nordisk (NYSE: NVO) launched the GLP-1 weight-loss revolution with its Wegovy and Ozempic injections, products that initially outpaced the company’s own manufacturing capacity.
That supply crunch created an opening for rival Eli Lilly (NYSE: LLY), which entered the market with its own GLP-1 treatments, Zepbound and Mounjaro, drugs clinically shown to deliver greater weight-loss results than Novo Nordisk’s offerings.
Eli Lilly’s more effective product quickly eroded Novo Nordisk’s early market leadership, shifting investor and consumer sentiment firmly toward the Indiana-based pharmaceutical giant.
Novo Nordisk has been working to reclaim its position, most visibly through the development and commercialization of a GLP-1 pill form of Wegovy, a format that prioritizes patient convenience over injection-based alternatives.
Eli Lilly has since entered the oral GLP-1 space as well, meaning Novo Nordisk’s first-mover advantage in pill format is already under competitive pressure from the same rival it faces in the injectable market.
A new partnership with Vivani Medical (NYSE American: VANI) could, however, represent a more significant strategic shift, one with the potential to reshape competitive dynamics across the entire GLP-1 industry.
Novo Nordisk’s approach appears to be centered on convenience as a differentiating factor, leaning into formats and delivery mechanisms that make GLP-1 therapy easier and more accessible for patients over the long term.
Eli Lilly, for its part, has been channeling its GLP-1 commercial success into broader business diversification, expanding into new therapeutic areas rather than concentrating exclusively on weight-loss treatments.
That diversification strategy carries its own logic, given that GLP-1 drugs accounted for roughly two-thirds of Eli Lilly’s total revenue in the second quarter of 2026, a level of concentration that presents meaningful risk if competitive or regulatory conditions shift.
From a valuation standpoint, the gap between the two companies is striking, with Eli Lilly trading at a price-to-earnings ratio of approximately 40 times earnings compared to Novo Nordisk’s considerably lower multiple of just 11.5 times earnings.
That valuation gap suggests the market has priced Novo Nordisk as a company in retreat, yet its continued innovation pipeline and new commercial partnerships indicate it remains a credible competitor in one of the pharmaceutical industry’s most lucrative growth segments.
Investors monitoring the GLP-1 space should weigh Novo Nordisk’s relative cheapness against its strategic momentum, as the Danish drugmaker continues to push back against Eli Lilly’s current market advantage.
